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phosphorothioate], an organophosphate 
(OP) insecticide first registered in 1958, is 
used to control pests on beef cattle, dairy 
cows, goats, horses, sheep, and swine [U.S. 
Environmental Protection Agency (EPA) 
1996]. Approximately 83% of the total 
chemical usage is on beef and dairy cattle. 
From 1990 to 1999, approximately 71,000 
pounds of coumaphos were used on 6 mil-
lion livestock annually (Smearman 2000). 
Coumaphos is applied primarily as a liquid 
(animal immersed in an insecticide-containing 
dip) but is also applied through a hand-held 
sprayer or dust formulation (U.S. EPA 1996). 
In addition to direct exposure to coumaphos 
among agricultural workers, family members 
of agricultural workers may be secondarily 
exposed in the home through contact with 
contaminated clothing or equipment (Arcury 
et al. 2007). The general population may be 
exposed through consumption of coumaphos-
treated food products—for example, milk 
from coumaphos-treated dairy cattle (Cardeal 
Zde and Dias Paes 2006). However, commer-
cial pesticide products containing the active 
ingredient coumaphos cannot be purchased 
by the general public. 
In vitro studies indicate coumaphos is not 
mutagenic using either Salmonella typhimu‑
rium or Escherichia coli assays with and without 
metabolic activation (U.S. EPA 1996). There 
was no evidence of carcinogenicity or increased 
tumor formation in two 2-year feeding stud-
ies in different strains of rat (dose range: 
1–25 ppm and 10 and 20 ppm, respectively), 
in one strain of mouse (dose range: 10 and 
20 ppm), or in one 1-year feeding study in 
beagle dogs (dose range: 1–90 ppm) (U.S. EPA 
1996). Dosing regimens in the four animal 
feeding studies were adequate to detect cancer 
based on range-finding studies. In 1994, the 
U.S. EPA classified coumaphos as a group E 
carcinogen: no evidence of carcinogenicity 
based on studies of at least two animal species. 
The U.S. EPA reaffirmed the decision in the 
year 2000 (U.S. EPA 2000). However, the 
relevant exposure to humans is the commercial 
product, which contains a mixture of active 
and inactive (inert) ingredients. 
A few epidemiologic studies have associ-
ated coumaphos exposure with cancer. Among 
adult male farmers, the risk of glioma was 
significantly increased for those who reported 
ever use of coumaphos [adjusted odds ratio 
(OR) = 5.9; 95% confidence interval (CI), 
1.1–32.0)] (Lee et al. 2005). In a pooled 
analy  sis from three case–control studies on 
multiple pesticide exposures and non-Hodgkin 
lymphoma (NHL) in midwestern states, the 
adjusted OR for NHL among those reporting 
use of coumaphos was 2.4 (95% CI, 1.0–5.8) 
(De Roos et al. 2003). In a nested case–control 
study within the Agricultural Health Study 
(AHS), researchers observed that among those 
with a family history of prostate cancer, those 
exposed to coumaphos had a 2-fold increased 
risk of prostate cancer (OR = 2.17; 95% 
CI, 1.24–3.82) compared with never users, 
although there was no increased risk among 
coumaphos users without a family history 
(Alavanja et al. 2003). Furthermore, although 
none of the 10 OP pesticides included in the 
AHS have been associated with prostate cancer 
in reports published to date, AHS researchers 
did observe a significant OR for the inter-
action [the interaction odds ratio (IOR), the 
OR for the cross-product term] between fam-
ily history of prostate cancer and ever use of 
certain OP pesticides with prostate cancer, 
including chlorpyrifos (IOR = 1.65; 95% CI, 
1.02–2.66, p = 0.04), phorate (IOR = 1.64; 
95% CI, 1.02–2.63, p = 0.04), fonofos (IOR 
= 2.04; 95% CI, 1.21–3.44, p = 0.008), and 
coumaphos (IOR = 2.58; 95% CI, 1.29–5.18, 
p = 0.008) (Alavanja et al. 2003). The pur-
pose of the present analysis was to evaluate 
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Ba c k g r o u n d: Coumaphos is an organophosphate livestock insecticide. Previous research in the 
Agricultural Health Study (AHS) cohort observed a positive association between coumaphos and 
prostate cancer in men with a family history of prostate cancer. 
oBjectives: This study was performed to determine the association between coumaphos and 
other major cancer sites and to explore the consistency of the association with prostate cancer early 
(1993–1999) and later (2000–2005) in AHS follow-up. 
Me t h o d s : This study included 47,822 male licensed pesticide applicators. Incident cases were 
ascertained by linkage to state cancer registries, and exposure data were collected by enrollment 
questionnaire. Poisson regression was used to estimate rate ratio (RR) and 95% confidence interval 
(CI) of cancer for coumaphos exposure controlling for potentially confounding variables. 
re s u l t s: Approximately 8% of applicators reported use of coumaphos; 8.5% reported a family 
history of prostate cancer. Cumulative exposure to coumaphos was not associated with cancer risk 
overall or with any major cancer site including prostate. In men with a family history of prostate 
cancer, we observed a positive association between ever use of coumaphos and prostate cancer in 
both early (RR = 2.07; 95% CI, 1.19–3.62, p-interaction = 0.005) and later (RR = 1.46; 95% CI, 
0.89–2.40; p-interaction = 0.11) periods of follow-up. Across all years, this association was statisti-
cally significant (RR = 1.65; 95% CI, 1.13–2.38; p-interaction = 0.004). 
co n c l u s i o n: Coumaphos was not associated with any cancer evaluated here. In men with a fam-
ily history of disease, there was evidence of an association between coumaphos and prostate cancer, 
possibly due to genetic susceptibility; however, other explanations, including chance, are plausible. 
key w o r d s : agriculture, cancer, coumaphos, insecticide, livestock, neoplasms, occupational expo-
sure, organophosphate, pesticide, prostate. Environ Health Perspect 118:92–96 (2010).  doi:10.1289/
ehp.0800446 available via http://dx.doi.org/ [Online 11 September 2009]Cancer incidence in a cohort of coumaphos applicators
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prospectively the association between cou-
maphos exposure and risk of total and site-
  specific cancers among men in the AHS across 
12 years of follow-up, as well as to examine the 
consistency later in follow-up (2000–2005) of 
the previous finding (1993–1999) of a higher 
risk of prostate cancer in men with coumaphos 
exposure but only if they have a family history 
of prostate cancer.
Material and Methods
Study population. The AHS is prospec-
tive cohort study comprising 57,310 pesti-
cide applicators in Iowa and North Carolina 
(Alavanja et al. 1996). Pesticide applicators 
were enrolled in the study between December 
1993 and December 1997 and on enrollment 
were asked to complete a self-administered 
written questionnaire that solicited informa-
tion on use of pesticides as well as lifestyle fac-
tors (Alavanja et al. 1996). More than 82% of 
private pesticide applicators in Iowa and North 
Carolina participated in the study. Records of 
cohort members were matched to Iowa and 
North Carolina state cancer registries to obtain 
information on cancer type, stage, and grade 
at diagnosis, and with the state death regis-
tries and the National Death Index to collect 
mortality information. This study includes 
all incident cases from enrollment through 
31 December 2005 (AHS, Data Release, 
version P1REL0612; unpublished data). 
Residential location was identified through the 
federal Internal Revenue Service address file, 
state motor vehicle registration records, recent 
telephone or mail contact with members, and 
the restricted-use pesticide license and certifica-
tion records of the departments of agriculture 
in Iowa and North Carolina. Study partici-
pants were censored for loss to follow-up, exit 
from the state of enrollment, receipt of a cancer 
diagnosis, or death; less than 2% of the cohort 
is lost to cancer incidence follow-up. All par-
ticipants provided informed consent, and the 
research protocol was approved by all appropri-
ate institutional review boards. 
Exposure assessment. Coumaphos exposure 
information was collected through the enroll-
ment questionnaire; questionnaires are avail-
able online (AHS 2008). Use of coumaphos 
was characterized using three different exposure 
metrics: ever/never use of the chemical, lifetime 
exposure days, and intensity-weighted lifetime 
exposure days. The lifetime exposure days met-
ric was calculated as the product of the total 
number of years of coumaphos application 
and the number of days per year of coumaphos 
application. The intensity-weighted lifetime 
exposure day metric incorporates lifetime expo-
sure days weighted by factors that may modify 
pesticide exposure, including application meth-
ods, mixing and equipment repair status, and 
use of personal protective equipment [(appli-
cation method + mixing status + equipment 
repair status) × (use of personal protective 
equipment)] (Dosemeci et al. 2002). Weights 
for these factors were based on monitoring data 
available in the   published literature. 
Statistical analysis. From the AHS pop-
ulation, female applicators (n = 1,563) were 
excluded, as there were too few exposed cases 
to perform an analyses (only one coumaphos-
exposed female applicator). To ensure that 
exposure preceded the development of cancer, 
we excluded prevalent cancer cases (n = 1,063). 
We also excluded participants who a) did not 
contribute person-years to the cohort (n = 10), 
b) did not provide birth date information 
(n = 2), c) were enrolled into the study as out-
of-state residents and continue to reside out of 
state (n = 285), or d) did not provide informa-
tion on use of coumaphos (n = 6,565). After 
exclusions, 47,822 participants contributing 
480,514 person-years at risk were included in 
this analysis. For the analysis of potential effect 
modification by presence of family history by 
time period of prostate cancer diagnosis, there 
were 217,047 person-years accrued by persons 
at risk for prostate cancer in the early period 
and 263,467 person-years of exposure accrued 
in the later period.
Associations between coumaphos and can-
cer risk were assessed by calculating incidence 
rate ratios (RRs) and 95% CIs using Poisson 
regression. We evaluated all cancers com-
bined, prostate, lung, colorectal, and lympho-
hematopoietic cancers (leukemia, NHL, 
multiple myeloma, and Hodgkin lymphoma), 
because there were five or more cancer cases 
per exposure category for these cancer sites. 
Lifetime exposure days and intensity-weighted 
exposure day metrics were categorized into 
tertiles based on the distribution among all 
cancer cases exposed to coumaphos. Cut 
points were based on all cancer cases, rather 
than on the baseline cohort, to assure ade-
quate numbers of cancer cases observed per 
tertile of exposure to perform a statistically 
robust analysis. To evaluate the possibility of 
residual (unidentified) confounding between 
those who never and ever used coumaphos, 
we performed all analyses using two referent 
groups: men not exposed to coumaphos and 
men with low exposure to coumaphos (bot-
tom tertile). We did not statistically adjust for 
multiple comparisons.
We performed Poisson regression analy-
ses adjusting for age (20–29, 30–39, 40–49, 
50–59, ≥ 60 years), education (high school 
education or less and greater than high school), 
state of residence, smoking (never, former, 
current), first-degree family history of organ-
specific cancers, fruit and vegetable consump-
tion (two or fewer per week, three to six per 
week, or seven or more per week), and total 
days of application of any pesticide. Further 
adjustment for alcohol consumption, race/eth-
nicity, enrollment year, use of other correlated 
pesticides, cattle farming, and other suspected 
cancer risk factors had minimal influence on 
the point estimates and were not included in 
the final model. We analyzed dose–response 
trends for coumaphos exposure and cancer 
risk by including the midpoint of each expo-
sure tertile as a continuous variable and testing 
for the statistical significance of the slope. 
Our secondary aim was to determine 
whether the observed association between cou-
maphos exposure and incident prostate cancer 
among those with a family history of prostate 
cancer in the AHS cohort between enrollment 
and December 1999 (Alavanja et al. 2003) was 
also observed among men diagnosed in the 
later period of follow-up. We evaluated pros-
tate cancer risk in association with ever/never 
use of coumaphos, stratifying by presence of 
family history of prostate cancer for both the 
early period of follow-up (1993–1999) and 
the later period of follow-up (2000–2005) 
and then across the entire period of follow-up, 
adjusting for age. We also investigated evidence 
of this potential effect modification using cat-
egories of lifetime exposure days across the 
entire follow-up period. We evaluated inter-
action by generating a cross-product term 
between coumaphos use and family history 
that was included in a multivariable model of 
prostate cancer; we quantified the significance 
of the interaction term using the Wald test 
(Rosner 1995). We evaluated whether the pre-
viously observed association was homogeneous 
by category of stage (categorized as local or as 
regional or distant) and histologic grade (cat-
egorized as well differentiated or moderately 
well differentiated or as poorly differentiated 
or undifferentiated) of prostate tumor at diag-
nosis. We also evaluated potential effect modi-
fication by family history of all cancer and for 
organ-specific cancers over the entire follow-up 
period. All tests for significance were two-sided 
with α = 0.05. Stata statistical software (release 
8.0; StataCorp., College Station, TX) was used 
for all analyses. 
Results
We observed 2,960 cancer cases, 1,196 of 
which were prostate, among the 44,133 men 
who reported no use of coumaphos, and we 
observed 258 cancers cases, 115 of which were 
prostate, among 3,689 men who reported using 
coumaphos. Among the 1,311 prostate can-
cers, 504 occurred early in follow-up (1993–
1999), and 807 occurred later in follow-up 
(2000–2005). More than one-half of the pros-
tate cancers identified were local stage (55%), 
13% were regional or distant, and 32% were 
not classified as to stage at diagnosis, possibly 
because the “watchful waiting” treatment strat-
egy was recommended for some cases. Most 
prostate tumors diagnosed in the cohort were 
moderately well or well differentiated (70%), 
26% were poorly differentiated, 0.3% of Christensen et al.
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tumors were undifferentiated, and the remain-
ing 3.3% of tumors were not determined as 
to histologic grade. Thirty-eight percent of the 
cohort reported a family history of any cancer. 
At enrollment, 7.7% of the study popula-
tion reported using coumaphos, and the range 
of annual exposure days reported by couma-
phos users was between 2.5 and 200 days per 
year. Table 1 displays the frequency of selected 
demographic characteristics of the study popu-
lation by categories of lifetime exposure days 
of coumaphos use. The participants were 
predominantly non-Hispanic white (97%) 
male private pesticide applicators. Compared 
with the low- and high-exposure groups, the 
unexposed group was generally younger and 
included a higher proportion of commercial 
applicator and nonwhites. Men in the unex-
posed group were less likely to have attained 
education beyond high school or to report 
a first-degree family member with a cancer 
diagnosis (Table 1). The mean (± SD) number 
of coumaphos exposure days over the lifetime 
was 7.5 ± 2.5 among men in the lowest expo-
sure group and 167.1 ± 402.1 among men 
in the highest exposure group. Those with a 
family history of prostate cancer had twice the 
risk of prostate cancer (OR = 2.02; 95% CI, 
1.73–2.37) (data not shown). 
RRs and 95% CIs for selected cancers by 
categories of coumaphos lifetime exposure 
days are shown in Table 2. Risk estimates for 
all cancers combined were not significantly 
different from the null, regardless of whether 
the reference group was men never exposed 
to coumaphos or men with low exposure. 
No cancer site displayed evidence of an expo-
sure–response gradient. Coumaphos lifetime 
exposure days were not related to the risk of 
other major cancer sites examined including 
prostate overall or when stratified by stage 
and grade of disease. Results were similar for 
analyses based on intensity-weighted lifetime 
exposure and are not shown here. 
Table 3 shows the association between 
coumaphos exposure and prostate cancer risk 
among men with and without a family history 
of prostate cancer. Results are presented for 
later in follow-up (2000–2005) and across the 
entire follow-up period by ever/never use of 
coumaphos. For comparison, results are also 
presented for early in follow-up (1993–1999), 
which was reported previously (Alavanja et al. 
2003). At baseline, approximately 8% of men 
not exposed to coumaphos reported a family 
history of prostate cancer, whereas 11% of 
coumaphos-exposed men reported a family 
history of prostate cancer. Among men with-
out a family history of prostate cancer, there 
was no association between coumaphos and 
prostate cancer early, later, or across the entire 
follow-up period. However, as observed early 
in follow-up, among men with a family his-
tory of prostate cancer, men who ever used 
coumaphos had a nonsignificantly higher risk 
of prostate cancer in follow-up years 2000–
2005 than men who did not use the chemical 
(RR = 1.46; 95% CI, 0.89–2.40). Across the 
entire 12 years of follow-up, the RR of pros-
tate cancer comparing ever versus never users 
among those with a family history of pros-
tate cancer was statistically significant (RR = 
1.65; 95% CI, 1.13–2.38), as was the test for 
interaction between coumaphos exposure and 
family history (p-interaction = 0.004). 
In a joint-effects analysis of the effect of 
both a positive family history of prostate can-
cer and self-reported ever use of coumaphos in 
association with prostate cancer (age-adjusted 
only), we observed the joint effect of both 
exposures in excess of the expected joint effect 
of the two independent exposures, measured 
on the multiplicative scale. Compared with 
the referent group of no reported family his-
tory of prostate cancer and no self-reported 
use of coumaphos, those who report use of 
the chemical but no family history have no 
increased risk of prostate cancer (RR = 0.86; 
95% CI, 0.69–1.10); those who report a fam-
ily history but no use of coumaphos have an 
almost 2-fold increased risk of prostate can-
cer (RR = 1.75; 95% CI, 1.49–2.05), and 
those who report both a positive family his-
tory of prostate cancer and self-report use of 
coumaphos have a nearly 3-fold increased 
risk of prostate cancer (RR = 2.89; 95% CI, 
2.04–4.09) compared with the expected joint 
effect of 1.5. Therefore, those who report both 
exposures have a nearly 2-fold increased risk 
beyond the expected joint effect of the two 
exposure factors if they were independent. 
Results of the joint effect model are similar in 
both periods of prostate cancer diagnosis—
that is, there is statistically significant effect 
modification of prostate cancer risk in both 
the later and earlier follow-up periods. 
We observed similar patterns of effect mod-
ification by family history of prostate cancer in 
Table 1. Characteristics of male AHS farmers and commercial applicators by coumaphos cumulative 
exposure category, 1993–2005 [no. (%)].
Coumaphos exposure
Characteristic None Lowa Highb
Total 44,133 (92.3) 1,526 (3.2) 2,163 (4.5)
Age at enrollment (years)
< 40  16,015 (36.3) 439 (28.8) 633 (29.3)
40–49 12,240 (27.7) 437 (28.6) 709 (32.8)
50–59 8,703 (19.7) 362 (23.7) 480 (22.2)
≥ 60 7,175 (16.3) 288 (18.9) 341 (15.8)
Mean age (years) 45.8  47.8 47.3
State of residence
Iowa 30,113 (68.2) 1,071 (70.2) 1,500 (69.4)
North Carolina 14,020 (31.8) 455 (29.8) 663 (30.7)
Type of applicator
Private 40,008 (90.7) 1,491 (97.7) 2,065 (95.5)
Commercial 4,125 (9.4) 35 (2.3) 98 (4.5)
Smoking history
None 23,298 (53.4) 882 (58.1) 1,206 (56.2)
Former 12,904 (29.6) 443 (29.2) 670 (31.2)
Current 7,426 (17.0) 193 (12.7) 270 (12.6)
Alcohol consumption
Never in last year 13,443 (30.9) 477 (31.4) 598 (27.9)
Ever in last year 30,099 (69.1) 1,042 (68.6) 1,548 (72.1)
Education
High school or less  24,442 (55.4) 724 (47.4) 1,054 (48.7)
Greater than high school 19,691 (44.6) 802 (52.6) 1,109 (51.3)
Family history of any cancer
No 25,286 (60.6) 769 (53.0) 1,103 (53.7)
Yes 16,433 (39.4) 681 (47.0) 950 (46.3)
Race
White 40,984 (96.9) 1,435 (98.0) 2,029 (97.8)
Nonwhite 1,299 (3.1) 29 (2.0) 46 (2.2)
Fruit/vegetable intake (servings per week)
2 or fewer per week 8,507 (19.6) 183 (12.1) 250 (11.7)
3–6 per week 17,390 (40.1) 559 (37.1) 809 (37.9)
≥ 7 per week 17,481 (40.3) 765 (50.8) 1,074 (50.4)
Cattle farmer
No 27,806 (63.0) 383 (25.1) 460 (21.3)
Yes 16,327 (37.0) 1,143 (74.9) 1,703 (78.7)
Years of follow-up (mean ± SD) 10.0 ± 2.1 10.1 ± 2.1 10.1 ± 2.1
Lifetime no. of days of all pesticide application (mean ± SD) 379.9 ± 604.0 381.3 ± 527.2 493.1 ± 683.0
Numbers may not sum to total because of missing data; percents may not sum to 100 because of rounding. Sample is 
restricted to men without previous cancer diagnosis with follow-up through 2005. 
aIncludes men in the first tertile of cumulative exposure days (1–8.74 days). bIncludes men in the top two tertiles of 
cumulative exposure days (≥ 8.75 days).Cancer incidence in a cohort of coumaphos applicators
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the relation between lifetime exposure days of 
coumaphos use and prostate cancer across the 
entire follow-up period (p-interaction = 0.02) 
(data not shown). Adjusting for age and using 
measures of cumulative exposure collected at 
enrollment, we observed increased risk when 
comparing the highest exposure group (i.e., 
upper half of exposed group) (n = 16 prostate 
cancer cases) with the nonexposed group (n = 
184 prostate cancer cases) among men with a 
family history of disease (RR = 1.36; 95% CI, 
0.81–2.26, p for trend = 0.04) and observed 
no increased risk between the top tertile (n = 
37 prostate cancer cases) and the nonexposed 
group (n = 935 prostate cancer cases) among 
men without a family history of disease (RR = 
0.78; 95% CI, 0.56–1.08, p for trend = 0.15). 
However, the risk of prostate cancer by lifetime 
exposure day category for men with a family 
history of disease was not monotonic. There 
were insufficient data available to investigate 
the exposure–response relation between cou-
maphos exposure and prostate cancer risk by 
presence of family history (yes/no) and by time 
period of follow-up (early and later periods). 
Discussion
To our knowledge, this is the largest exami-
nation of any group occupationally exposed 
to coumaphos. We observed no overall asso-
ciation between reported use of coumaphos 
and risk of total cancer or cancers of the pros-
tate, lung, or lymphohematopoietic system, 
or colo  rectal cancer. The lack of observed 
association between coumaphos exposure and 
all lymphohematopoietic cancers combined 
may be explained by the low percentage of 
coumaphos-exposed lymphohematopoietic 
cancers as well as the known heterogeneity 
among lympho  hematopoietic cancers. We had 
no a priori hypotheses regarding the potential 
association between coumaphos use and lung 
cancer or colorectal cancer. Similar to an earlier 
AHS report, we observed a positive association 
between ever use of coumaphos and incident 
prostate cancer among those with a family his-
tory of prostate cancer, but not among those 
without a family history of prostate cancer, in 
a later follow-up period (2000–2005) as well 
as across all years of follow-up (1993–2005). 
However, the observed association was stron-
ger in the early period than in the later period 
of follow-up. The current study includes more 
than twice as many prostate cancer cases and 
6 additional years of follow-up than the earlier 
report (Alavanja et al. 2003). Further analy-
sis suggests that the differences between early 
and later time periods may be due in part to 
a difference in the number of lifetime days 
of exposure. Using lifetime exposure days 
measured at the beginning of follow-up, cou-
maphos-exposed prostate cancer cases with 
a family history of disease in the early period 
reported an average of 130 lifetime exposure 
days, whereas coumaphos-exposed cases with 
a family history of prostate cancer in the later 
period reported an average of 40 lifetime expo-
sure days at baseline. Therefore, the attenua-
tion in risk observed in the later time period of 
prostate cancer diagnosis may be attributable 
to lower cumulative exposure. However, we 
acknowledge that other explanations are possi-
ble. The use of exposure information collected 
at enrollment may have led to nondifferential 
exposure misclassification in this study, espe-
cially for the latter half of follow-up, or the 
association observed early in follow-up could 
have been due to outliers in this period, both 
of which could explain why the association 
is less strong later compared with earlier in 
follow-up.
Although the mechanism through which 
coumaphos exposure may affect prostate 
cancer risk is not known at this time, OP 














All cancer None 2,960 17,260 1.00  — 
1.0–8.74 114 655 1.00 (0.82–1.23) 1.00 
8.75–38.75 71 392 0.92 (0.71–1.20) 0.92 (0.67–1.28)
> 38.75 73 397 0.96 (0.74–1.25) 0.96 (0.69–1.33)
p for trend 0.70 0.76
Prostate None 1,196 6,860 1.00  — 
1.0–8.74 57 346 1.17 (0.88–1.56) 1.00 
8.75–38.75 28 145 0.84 (0.60–1.26) 0.72 (0.44–1.17)
> 38.75 30 187 0.93 (0.62–1.41) 0.80 (0.48–1.31)
p for trend 0.68 0.34
Lung None 288 1,725 1.00  — 
1.0–8.74 10 48 1.24 (0.64–2.42) 1.00 
8.75–38.8 5 26 1.03 (0.43–2.52) 0.84 (0.28–2.50)
> 38.8 7 42 0.78 (0.29–2.11) 0.63 (0.19–2.05)
p for trend 0.67 0.52
Colorectal None 342 2,076 1.00  — 
1.0–8.74 12 71 0.80 (0.41–1.55) 1.00
8.75–38.8 5 25 0.52 (0.19–1.40) 0.65 (0.20–2.13)
> 38.8 6 22 0.84 (0.37–1.89) 1.06 (0.38–2.97)
p for trend 0.49 0.65
Lymphohematopoietic None 295 1,740 1.00  —
1.0–8.74 11 54 0.86 (0.44–1.68) 1.00 
8.75–38.8 7 45 0.85 (0.38–1.91) 0.99 (0.35–2.77)
> 38.8 7 31 1.08 (0.51–2.30) 1.26 (0.47–3.38)
p for trend 0.91 0.79
aCancer registry follow-up through 2005. bAdjusted for age, education, state, smoking, family history, fruit and vegetable 
consumption, total days of application of any pesticide. cThe nonexposed are those who reported never using couma-
phos; the low-exposed referents are those in the low-exposure tertile.
Table 3. Association between ever use of coumaphos and prostate cancer RRs (95% CI) by family history 
of prostate cancer, early (1993–1999) and later (2000–2005) in cohort follow-up, AHS.
Family history of prostate cancer
Noa Yesa Interaction
Time period Cases P-Y RRb (95% CI) Cases P-Y RRb (95% CI) RRc (95% CI)
Early (1993–1999)d
Never 353 889 1.00 71 200 1.00 — 
Ever 25 56 0.78 (0.52–1.17) 15 41 2.07 (1.19–3.62) 2.67 (1.34–5.31)
p for interaction 0.005 
Late (2000–2005)
Never 582 4,520 1.00 113 859 1.00 —
Ever 50 403 0.93 (0.69–1.23) 18 144 1.46 (0.89–2.40) 1.60 (0.90–2.82)
p for interaction 0.113 
Entire period
Never 935 5,409 1.00 184 1,059 1.00  —
Ever 75 459 0.87 (0.68–1.10) 33 185 1.65 (1.13–2.38) 1.91 (1.23–2.95)
p for interaction 0.004 
P-Y, person-years. Using the lifetime exposure days metric we examined prostate cancer risk by coumaphos exposure 
response patterns. The number of exposed cases was small, making the following risk estimates unstable: none, low 
(> 8.75 days), high (> 8.75 days), RR without prostate cancer family history 1.0, 0.98 (0.71–1.35), and 0.78 (0.56–1.08), 
p-trend 0.15, and with a family history, 1.0, 2.06 (1.25–3.38), and 1.36 (0.81–2.26), p-trend 0.04, p-interaction 0.009.
aSeven coumaphos-exposed prostate cancer cases were missing information on family history. bAdjusted for age. 
cAdjusted for age and family history of prostate cancer. The interaction RR is the exponentiation of the interaction coef-
ficient and can be interpreted as the ratio of the joint effect of both exposures versus the expected joint effect of each 
exposure singly, assuming a multiplicative model. dPreviously reported by Alavanja et al. (2003). Christensen et al.
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pesticides have been shown to induce oxida-
tive stress (Bagchi et al. 1995), which if not 
repaired may lead to cellular damage and dis-
ruption of DNA repair mechanisms (Muniz 
et al. 2008). In addition, limited experimen-
tal research suggests that OP pesticides may 
influence sex steroid hormone homeostasis 
(Gore 2002; Kang et al. 2004; Svechnikov 
et al. 2005; Tamura et al. 2001; Usmani et al. 
2003, 2006), altering the level of circulating 
and/or bioavailable sex steroid hormones. This 
may affect cell proliferation or other important 
functions ultimately affecting prostate cancer 
risk (Hsing et al. 2002; Platz and Giovannucci 
2004). Although circulating levels of steroid 
hormone have not been significantly associated 
with prostate cancer (Endogenous Hormones 
and Prostate Cancer Collaborative Group et al. 
2008), some question the degree to which 
circulating hormone concentration reflects 
intraprostatic concentrations, the exposure of 
interest, and encourage continued research 
in this area (Hsing et al. 2008). Therefore, 
variation in genes involved in DNA repair 
or hormone synthesis and regulation, among 
other pathways, may help explain the observed 
association between coumaphos use and pros-
tate cancer among men with a family history 
of disease. 
Strengths of the AHS include the prospec-
tive nature of the study, high participation 
rates, and low loss to cancer follow-up. Given 
the extensive exposure information collected 
through the AHS, we were able to control for 
exposure to other pesticides as well as other 
occupational and lifestyle factors. Some limi-
tations should also be noted. The small per-
centage of applicators reporting ever use of 
coumaphos (7.7%) disallowed investigation of 
associations between coumaphos use and many 
cancer sites for which too few coumaphos-
exposed cancer cases occurred for a robust 
statistical analysis. Research in another pro-
spective cohort study reveals that self-reported 
family history of prostate cancer among men is 
moderately reliable. Comparing self-reported 
family history of cancer in the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) cohort study 
with Surveillance, Epidemiology and End 
Results (SEER) Program results indicates that 
men self-report 52% (95% CI, 50–55) of the 
expected number of prostate cancers among 
their first-degree relatives (Pinsky et al. 2003). 
Although in general, the AHS cohort has been 
found to have provided valid (Hoppin et al. 
2002) and reliable (Blair et al. 2002) estimates 
of exposure, inaccurate recall is undoubtedly a 
limitation and would introduce random expo-
sure misclassification, which would attenuate 
the RR (Greenland 1980). 
We observed no association with cancer 
overall or any of the specific cancers investi-
gated. We observed an increased risk of pros-
tate cancer in association with coumaphos 
exposure among men with a family history of 
prostate cancer but not among men without 
a family history in both early (1993–1999) 
and later periods in cohort follow-up 
(2000–2005), although the interaction RR 
in the early period is stronger than in the later 
period. This finding suggests further moni-
toring of the cohort is warranted. Possible 
genetic susceptibility to prostate cancer associ-
ated with coumaphos exposure is suggested 
and should be investigated; however, because 
the magnitude of the association decreased 
over time, alternative explanations, including 
chance, need to be considered.
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